SignalCorporate
Poxel Reports Revenue for the Third Quarter of 2026
High-priority alert based on source significance and keyword relevance.
Context
What happened: Poxel reported third quarter 2026 revenue of €1,951k, including royalties from Sumitomo Pharma's TWYMEEG sales in Japan and a retroactive adjustment to second quarter royalties.
Key numbers: TWYMEEG net sales in Japan were JPY 2.9 billion (€16.3 million) in Q3 2026, up 29% year over year, and JPY
Why it matters: Poxel generates positive net royalties for the first time in Sumitomo Pharma's fiscal 2026, and Sumitomo expects TWYMEEG net sales above JPY 10 billion, which would lift the royalty rate to 12% and trigger a JPY 1 billion bonus. Proceeds go to repaying OrbiMed bonds.
Coverage: 3 outlets in 24h
What changed
Poxel reported third quarter 2026 revenue of €1,951k, including royalties from Sumitomo Pharma's TWYMEEG sales in Japan and a retroactive adjustment to second quarter royalties.
Why it matters
Poxel generates positive net royalties for the first time in Sumitomo Pharma's fiscal 2026, and Sumitomo expects TWYMEEG net sales above JPY 10 billion, which would lift the royalty rate to 12% and trigger a JPY 1 billion bonus. Proceeds go to repaying OrbiMed bonds.